ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 05/24/23

2023-05-24 14:15:54 ET Summary Crisis of confidence in prior management (related to full clinical hold in February for FTX-6058 in SCD) led to currently cheap valuation. New CEO (appointed mid May) sold prior companies to Pfizer and Sobi. Primary endpoint for losmapimod in FSH...

2023-05-23 12:15:47 ET Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) announced Tuesday that patients with a rare form of hypercholesterolemia indicated a 44% – 48% reduction of LDL-Cholesterol, also known as “bad” cholesterol, after receiving its experimental R...

- 44-48% Mean Reductions in LDL-C Achieved on Top of Continued Standard of Care - Phase 3 Planning is Ongoing Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RN...

2023-05-19 17:07:00 ET Summary A Phase 3 study for treatment of ARO-AOPC3 for FCS has completed enrollment. The Phase 3 fazirsiran study started, earning a $40 million milestone. Cash ended Q1 at $560 million, so well positioned to get to Phase 3 results. Arrowhead Pharm...

- Primary Study Completion Anticipated in the Second Quarter of 2024 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome. ...

2023-05-02 20:42:04 ET Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2023 Earnings Conference Call May 2, 2023 4:30 P.M. ET Company Participants Vincent Anzalone - Vice President, Investor Relations Christopher Anzalone - President and Chief Executive Officer Javier ...

2023-05-02 17:04:04 ET Arrowhead Pharmaceuticals press release ( NASDAQ: ARWR ): Q2 GAAP EPS of $0.45 beats by $1.06 . Revenue of $146.26M (-3.6% Y/Y) beats by $100.78M . For further details see: Arrowhead Pharmaceuticals GAAP EPS of $0.45 beats by $1.06,...

2023-05-02 17:00:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Opportunity Fund® climbed 17.96% (Institutional S...

- Conference Call and Webcast Today, May 2, 2023 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4:30 p.m. ET to discuss the...

2023-05-01 23:53:08 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Arrowhead Pharmaceuticals and Meta propelled my portfolio again to all-time highs and mar...